{"protocolSection": {"identificationModule": {"nctId": "NCT00739297", "orgStudyIdInfo": {"id": "0476-388"}, "secondaryIdInfos": [{"id": "MK0476-388"}, {"id": "2008_542"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)", "officialTitle": "A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK0476 in Patients With Chronic Asthma"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-19", "studyFirstSubmitQcDate": "2008-08-19", "studyFirstPostDateStruct": {"date": "2008-08-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-01-14", "resultsFirstSubmitQcDate": "2010-03-25", "resultsFirstPostDateStruct": {"date": "2010-04-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will test the safety and effectiveness of a range of doses of MK0476 (montelukast) compared to placebo on improved lung function in patients with chronic asthma."}, "conditionsModule": {"conditions": ["Chronic Asthma"], "keywords": ["Chronic asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 68, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "PLACEBO_COMPARATOR", "description": "montelukast Placebo", "interventionNames": ["Drug: Comparator: montelukast", "Drug: Comparator: placebo"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "montelukast", "interventionNames": ["Drug: Comparator: montelukast"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "montelukast", "interventionNames": ["Drug: Comparator: montelukast"]}, {"label": "4", "type": "EXPERIMENTAL", "description": "montelukast", "interventionNames": ["Drug: Comparator: montelukast"]}], "interventions": [{"type": "DRUG", "name": "Comparator: montelukast", "description": "5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.", "armGroupLabels": ["1", "2", "3", "4"], "otherNames": ["SINGULAIR\u00ae, PROAIR\u00ae HFA"]}, {"type": "DRUG", "name": "Comparator: placebo", "description": "5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in FEV1 Over 4 Hours", "description": "FEV1 measurements taken at 0 (=baseline), 10, 20, 30, 45, 60, 120, 180 and 240 minutes contributed to the average change from baseline over 4 hours. The number of minutes between consecutive measurements was used as weighting factor. The time-weighted average change was standardized by dividing by the time associated with the last measurement.", "timeFrame": "0 (=baseline) to 4 hours after treatment with montelukast"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FEV1 Over 90 Minutes After Albuterol/Placebo Administration", "description": "FEV1 measurements taken at 0 (=baseline), 15, 30, 60, and 90 minutes after albuterol/placebo administration contributed to the average change from baseline over 90 minutes. The number of minutes between consecutive measurements was used as weighting factor. The time-weighted average change was standardized by dividing by the time associated with the last measurement.", "timeFrame": "4 hours (equals time point at which albuterol or albuterol placebo is administered) to 5.5 hours after treatment with montelukast"}], "otherOutcomes": [{"measure": "Change From Baseline in FEV1 at 8 Hours After Treatment With Montelukast", "description": "Average change from baseline in FEV1 at 8 hours after single dose montelukast administration.", "timeFrame": "0 (baseline) and 8 hours after treatment with montelukast"}, {"measure": "Change From Baseline in FEV1 at 24 Hours After Treatment With Montelukast", "description": "Average change from baseline in FEV1 at 24 hours after single dose montelukast administration.", "timeFrame": "0 (baseline) and 24 hours after treatment with montelukast"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* A person is 15 to 65 years of age. A person has had chronic asthma for at least one year\n\nExclusion Criteria:\n\n* A person is a smoker or has smoked more that a pack a day for more than 10 years before stopping\n* A person has other lung disorders such as COPD (chronic obstructive pulmonary disorder)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "20936994", "type": "DERIVED", "citation": "Philip G, Pedinoff A, Vandormael K, Tymofyeyev Y, Smugar SS, Reiss TF, Korenblat PE. A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma. J Asthma. 2010 Dec;47(10):1078-84. doi: 10.3109/02770903.2010.520100. Epub 2010 Nov 3."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "117 participants were screened; 49 were excluded. Randomized patients met the following criteria during the prestudy period: FEV1 (Forced expiratory volume in one second) 50-85% predicted while withholding short-acting beta agonist (SABA) and reversibility of airway obstruction \\>12% following SABA at Visits 1 and 2.", "recruitmentDetails": "Patients were recruited from 6 centers in the United States between July and December 2008.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Patients are randomized to receive placebo for montelukast on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions, either albuterol or placebo for albuterol is administered 4 hours after placebo for montelukast. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "FG001", "title": "25 mcg Montelukast", "description": "Patients are randomized to receive montelukast 25 mcg (microgram) on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 25 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "FG002", "title": "100 mcg Montelukast", "description": "Patients are randomized to receive montelukast 100 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 100 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "FG003", "title": "250 mcg Montelukast", "description": "Patients are randomized to receive montelukast 250 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 250 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "FG004", "title": "500 mcg Montelukast", "description": "Patients are randomized to receive montelukast 500 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 500 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "FG005", "title": "1000 mcg Montelukast", "description": "Patients are randomized to receive montelukast 1000 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 1000 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "FG006", "title": "Total", "description": "Consistent with the \"incomplete-block\" design of this study, 6 treatments (placebo and 5 active-dose levels) were administered during only 4 treatment periods. In other words, in this 4-period crossover design, no patient received all 6 treatments and thus some treatments were not\n\nreceived by all of the patients. Therefore, the TOTAL number of participants across ALL the dose levels provides the best metric to follow the consistency of patient flow from one treatment period to the next treatment period."}], "periods": [{"title": "First Intervention (Visit 3 to Visit 4)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "19"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "68"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "19"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "68"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}, {"title": "First Washout Period of 4-7 Days", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "19"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "68"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "17"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}]}]}, {"title": "Second Intervention (Visit 5 to Visit 6)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "14"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "10"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "14"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "10"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}, {"title": "Second Washout Period of 4-7 Days", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "14"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "10"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "14"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "10"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}, {"title": "Third Intervention (Visit 7 to Visit 8)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "18"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "18"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}, {"title": "Third Washout Period of 4-7 Days", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "18"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "18"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}, {"title": "Fourth Intervention(Visit 9 to Visit 10)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "15"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "15"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "65"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Patient unable to attend last visit", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "Combined participants from all arms."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "68"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.1", "spread": "12.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "36"}]}]}]}, {"title": "FEV1 (Forced Expiratory Volume in One Second)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "L (Liter)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.44", "spread": "0.63"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in FEV1 Over 4 Hours", "description": "FEV1 measurements taken at 0 (=baseline), 10, 20, 30, 45, 60, 120, 180 and 240 minutes contributed to the average change from baseline over 4 hours. The number of minutes between consecutive measurements was used as weighting factor. The time-weighted average change was standardized by dividing by the time associated with the last measurement.", "populationDescription": "Full analysis set (FAS) population which included all randomized patients who took at least one dose of post randomization study drug (Montelukast or placebo) at either of the intervention visits and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L (Liter)", "timeFrame": "0 (=baseline) to 4 hours after treatment with montelukast", "groups": [{"id": "OG000", "title": "Placebo", "description": "Patients are randomized to receive placebo for montelukast on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions, either albuterol or placebo for albuterol is administered 4 hours after placebo for montelukast. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG001", "title": "25 mcg Montelukast", "description": "Patients are randomized to receive montelukast 25 mcg (microgram) on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 25 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG002", "title": "100 mcg Montelukast", "description": "Patients are randomized to receive montelukast 100 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 100 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG003", "title": "250 mcg Montelukast", "description": "Patients are randomized to receive montelukast 250 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 250 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG004", "title": "500 mcg Montelukast", "description": "Patients are randomized to receive montelukast 500 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 500 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG005", "title": "1000 mcg Montelukast", "description": "Patients are randomized to receive montelukast 1000 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 1000 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "66"}, {"groupId": "OG004", "value": "25"}, {"groupId": "OG005", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "lowerLimit": "-0.03", "upperLimit": "0.10"}, {"groupId": "OG001", "value": "0.07", "lowerLimit": "0.00", "upperLimit": "0.14"}, {"groupId": "OG002", "value": "0.13", "lowerLimit": "0.06", "upperLimit": "0.20"}, {"groupId": "OG003", "value": "0.10", "lowerLimit": "0.04", "upperLimit": "0.16"}, {"groupId": "OG004", "value": "0.09", "lowerLimit": "0.01", "upperLimit": "0.16"}, {"groupId": "OG005", "value": "0.12", "lowerLimit": "0.05", "upperLimit": "0.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.04", "ciPctValue": "95", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.08", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.10", "ciPctValue": "95", "ciLowerLimit": "0.04", "ciUpperLimit": "0.15", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.06", "ciPctValue": "95", "ciLowerLimit": "0.02", "ciUpperLimit": "0.11", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.05", "ciPctValue": "95", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.11", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.08", "ciPctValue": "95", "ciLowerLimit": "0.04", "ciUpperLimit": "0.13", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline in FEV1 Over 90 Minutes After Albuterol/Placebo Administration", "description": "FEV1 measurements taken at 0 (=baseline), 15, 30, 60, and 90 minutes after albuterol/placebo administration contributed to the average change from baseline over 90 minutes. The number of minutes between consecutive measurements was used as weighting factor. The time-weighted average change was standardized by dividing by the time associated with the last measurement.", "populationDescription": "Full analysis set (FAS) population which included all randomized patients who took at least one dose of post randomization study drug (albuterol or matching placebo) 4 hours after treatment with montelukast at either of the intervention visits and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "4 hours (equals time point at which albuterol or albuterol placebo is administered) to 5.5 hours after treatment with montelukast", "groups": [{"id": "OG000", "title": "Montelukast+Albuterol", "description": "Montelukast (data for each patient are pooled across all 3 of the active doses received by that patient) +Albuterol (data for each patient are pooled across all 3 administrations of active albuterol, as added to active montelukast)"}, {"id": "OG001", "title": "Montelukast+ Placebo", "description": "Montelukast (data for each patient are pooled across all 3 of the active doses received by that patient) +Placebo for Albuterol (data for each patient are pooled across all 3 administrations of placebo for albuterol, as added to active montelukast)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.34", "lowerLimit": "0.22", "upperLimit": "0.45"}, {"groupId": "OG001", "value": "0.15", "lowerLimit": "0.06", "upperLimit": "0.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.19", "ciPctValue": "95", "ciLowerLimit": "0.04", "ciUpperLimit": "0.34", "estimateComment": "Repeated measures model with terms for treatment (Albuterol/Placebo), dose, treatment-by-dose interaction and baseline FEV1"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in FEV1 at 8 Hours After Treatment With Montelukast", "description": "Average change from baseline in FEV1 at 8 hours after single dose montelukast administration.", "populationDescription": "Full analysis set (FAS) population which included all randomized patients who took at least one dose of post randomization study drug (Montelukast or placebo) at either of the intervention visits and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "0 (baseline) and 8 hours after treatment with montelukast", "groups": [{"id": "OG000", "title": "Placebo", "description": "Patients are randomized to receive placebo for montelukast on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions, either albuterol or placebo for albuterol is administered 4 hours after placebo for montelukast. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG001", "title": "25 mcg Montelukast", "description": "Patients are randomized to receive montelukast 25 mcg (microgram) on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 25 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG002", "title": "100 mcg Montelukast", "description": "Patients are randomized to receive montelukast 100 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 100 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG003", "title": "250 mcg Montelukast", "description": "Patients are randomized to receive montelukast 250 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 250 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG004", "title": "500 mcg Montelukast", "description": "Patients are randomized to receive montelukast 500 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 500 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG005", "title": "1000 mcg Montelukast", "description": "Patients are randomized to receive montelukast 1000 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 1000 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "66"}, {"groupId": "OG004", "value": "24"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "-0.02", "upperLimit": "0.14"}, {"groupId": "OG001", "value": "0.11", "lowerLimit": "0.03", "upperLimit": "0.20"}, {"groupId": "OG002", "value": "0.13", "lowerLimit": "0.04", "upperLimit": "0.23"}, {"groupId": "OG003", "value": "0.11", "lowerLimit": "0.03", "upperLimit": "0.19"}, {"groupId": "OG004", "value": "0.12", "lowerLimit": "0.02", "upperLimit": "0.22"}, {"groupId": "OG005", "value": "0.14", "lowerLimit": "0.05", "upperLimit": "0.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.06", "ciPctValue": "95", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.12", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.07", "ciPctValue": "95", "ciLowerLimit": "-0.00", "ciUpperLimit": "0.15", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.05", "ciPctValue": "95", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.11", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.06", "ciPctValue": "95", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.14", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.08", "ciPctValue": "95", "ciLowerLimit": "0.01", "ciUpperLimit": "0.15", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in FEV1 at 24 Hours After Treatment With Montelukast", "description": "Average change from baseline in FEV1 at 24 hours after single dose montelukast administration.", "populationDescription": "Full analysis set (FAS) population which included all randomized patients who took at least one dose of post randomization study drug (Montelukast or placebo) at either of the intervention visits and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "0 (baseline) and 24 hours after treatment with montelukast", "groups": [{"id": "OG000", "title": "Placebo", "description": "Patients are randomized to receive placebo for montelukast on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions, either albuterol or placebo for albuterol is administered 4 hours after placebo for montelukast. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG001", "title": "25 mcg Montelukast", "description": "Patients are randomized to receive montelukast 25 mcg (microgram) on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 25 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG002", "title": "100 mcg Montelukast", "description": "Patients are randomized to receive montelukast 100 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 100 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG003", "title": "250 mcg Montelukast", "description": "Patients are randomized to receive montelukast 250 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 250 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG004", "title": "500 mcg Montelukast", "description": "Patients are randomized to receive montelukast 500 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 500 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}, {"id": "OG005", "title": "1000 mcg Montelukast", "description": "Patients are randomized to receive montelukast 1000 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 1000 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "66"}, {"groupId": "OG004", "value": "25"}, {"groupId": "OG005", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "lowerLimit": "-0.06", "upperLimit": "0.09"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "-0.03", "upperLimit": "0.13"}, {"groupId": "OG002", "value": "0.10", "lowerLimit": "0.01", "upperLimit": "0.19"}, {"groupId": "OG003", "value": "0.06", "lowerLimit": "-0.01", "upperLimit": "0.13"}, {"groupId": "OG004", "value": "0.08", "lowerLimit": "-0.01", "upperLimit": "0.18"}, {"groupId": "OG005", "value": "0.09", "lowerLimit": "0.01", "upperLimit": "0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.04", "ciPctValue": "95", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.10", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.09", "ciPctValue": "95", "ciLowerLimit": "0.01", "ciUpperLimit": "0.17", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.05", "ciPctValue": "95", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.10", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.07", "ciPctValue": "95", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.15", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Difference in Least-Squares Means", "paramValue": "0.08", "ciPctValue": "95", "ciLowerLimit": "0.01", "ciUpperLimit": "0.15", "estimateComment": "Mixed effects model with terms for treatment (including dose of montelukast), period and baseline covariate."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Patients are randomized to receive placebo for montelukast on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions, either albuterol or placebo for albuterol is administered 4 hours after placebo for montelukast. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment).", "seriousNumAffected": 0, "seriousNumAtRisk": 67, "otherNumAffected": 4, "otherNumAtRisk": 67}, {"id": "EG001", "title": "25 mcg Montelukast", "description": "Patients are randomized to receive montelukast 25 mcg (microgram) on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 25 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment).", "seriousNumAffected": 0, "seriousNumAtRisk": 41, "otherNumAffected": 1, "otherNumAtRisk": 41}, {"id": "EG002", "title": "100 mcg Montelukast", "description": "Patients are randomized to receive montelukast 100 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 100 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment).", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 0, "otherNumAtRisk": 30}, {"id": "EG003", "title": "250 mcg Montelukast", "description": "Patients are randomized to receive montelukast 250 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 250 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment).", "seriousNumAffected": 0, "seriousNumAtRisk": 66, "otherNumAffected": 3, "otherNumAtRisk": 66}, {"id": "EG004", "title": "500 mcg Montelukast", "description": "Patients are randomized to receive montelukast 500 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 500 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment).", "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 3, "otherNumAtRisk": 25}, {"id": "EG005", "title": "1000 mcg Montelukast", "description": "Patients are randomized to receive montelukast 1000 mcg on either Intervention I (Visit 3), Intervention II (Visit 5), Intervention III (Visit 7) or Intervention IV (Visit 9). At all interventions either albuterol or placebo for albuterol is administered 4 hours after montelukast 1000 mcg. During the washout periods separating the intervention periods, patients received no study treatment (i.e., patients did not receive montelukast or placebo treatment).", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 0, "otherNumAtRisk": 36}], "otherEvents": [{"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 66}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}